NovoCure and Supernus Signal Growth in Q4 2025 Earnings Amid Product Expansions
NovoCure and Supernus Pharmaceuticals reported Q4 2025 results, highlighting a pivotal year for commercial expansion in oncology and CNS markets. Both companies are navigating the transition from R&D-heavy phases to sustained commercial growth following key regulatory milestones.
Beat this week
Last 7 days · Pharma
Impact 5.9/10 (+0.4 vs prior). Counts are stories in our record, not a market forecast.
Open the change reportCoverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 43 percentage points.
This story sits in Pharma — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.
Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.
Biotech briefing
Key takeaways
- NovoCure and Supernus Pharmaceuticals reported Q4 2025 results, highlighting a pivotal year for commercial expansion in oncology and CNS markets.
- Both companies are navigating the transition from R&D-heavy phases to sustained commercial growth following key regulatory milestones.
In this briefing
Mentioned
Key Intelligence
Key Facts
- 1NovoCure reported Q4 2025 results following the first full year of Optune Lua's commercial launch in NSCLC.
- 2Supernus Pharmaceuticals continues to focus on Qelbree's growth in the adult ADHD market as a non-stimulant alternative.
- 3NovoCure's R&D focus remains on the PANOVA-3 (pancreatic) and METIS (brain metastases) clinical trials.
- 4Supernus is navigating the regulatory path for SPN-830, an apomorphine infusion pump for Parkinson's disease.
- 5Both companies are transitioning from R&D-centric models to commercial-scale operations in oncology and CNS.
Analysis
The conclusion of the 2025 fiscal year marks a significant turning point for NovoCure Limited (NVCR), as the company moves beyond its traditional stronghold in glioblastoma multiforme (GBM) into the broader oncology market. The Q4 2025 earnings call underscored the commercial momentum of Optune Lua, which received FDA approval in late 2024 for post-platinum non-small cell lung cancer (NSCLC). This launch represents the first major indication expansion for NovoCure’s Tumor Treating Fields (TTFields) technology in over a decade, fundamentally altering the company's revenue profile. Analysts are closely monitoring the adoption rates among oncologists, as the non-invasive nature of TTFields offers a unique value proposition compared to systemic therapies, though the logistical requirements of the wearable device remain a hurdle for some patient populations.
Financially, NovoCure’s performance in the fourth quarter reflects the high costs associated with this commercial scale-up. While revenue growth is being driven by the expanded label, the company continues to invest heavily in its clinical pipeline, specifically the PANOVA-3 trial in pancreatic cancer and the METIS trial for brain metastases. The strategic challenge for NovoCure in 2026 will be balancing these intensive R&D expenditures with the need to demonstrate a clear path to profitability. The market remains cautiously optimistic, viewing the NSCLC launch as a litmus test for the platform's versatility. If NovoCure can successfully penetrate the lung cancer market, it validates the TTFields mechanism of action across multiple solid tumor types, potentially de-risking future indications.
Simultaneously, Supernus Pharmaceuticals (SUPN) reported its Q4 results, focusing on the continued ramp-up of Qelbree in the competitive ADHD market.
Simultaneously, Supernus Pharmaceuticals (SUPN) reported its Q4 results, focusing on the continued ramp-up of Qelbree in the competitive ADHD market. Throughout 2025, Supernus has sought to capture market share from established stimulants by positioning Qelbree as a non-stimulant alternative with a favorable safety profile. The fourth-quarter data suggests that the adult indication for Qelbree is becoming a primary growth driver, offsetting the natural erosion of older products in the company’s portfolio. However, the shadow of SPN-830, the company’s apomorphine infusion pump for Parkinson’s disease, continues to loom over its regulatory narrative. After facing multiple Complete Response Letters (CRLs) in previous years, the status of the resubmission remains a focal point for investors seeking a catalyst for the CNS-focused firm.
What to Watch
Beyond these two leaders, the broader biotech earnings landscape in late February 2026 shows a sector in transition. Companies are increasingly being rewarded for commercial execution rather than just clinical potential. For Supernus, this means maximizing the lifecycle of its Parkinson’s franchise, including Gocovri, while navigating the complex payer landscape for new ADHD treatments. The integration of digital health tools and patient support programs has become a standard requirement for both NovoCure and Supernus to ensure long-term adherence to their respective therapies. As the industry moves into 2026, the focus shifts to how these companies will manage pricing pressures and the potential for generic competition in the wider CNS and oncology spaces.
Looking ahead, the next six months will be critical for both entities. NovoCure is expected to release top-line data from its pancreatic cancer studies, which could further expand its addressable market. For Supernus, the focus will remain on the potential FDA decision regarding SPN-830 and the continued expansion of Qelbree’s market share. Investors should watch for updates on international expansion, particularly for NovoCure in the European and Asian markets, where regulatory environments for medical devices differ significantly from the United States. The ability of these mid-cap pharma players to maintain growth in a high-interest-rate environment will serve as a bellwether for the health of the broader biotech innovation ecosystem.
Cite This Page
"NovoCure and Supernus Signal Growth in Q4 2025 Earnings Amid Product Expansions." Biotech Intelligence Brief, February 26, 2026. https://getbiobrief.com/story/novocure-supernus-q4-2025-earnings-analysis
How we covered this story
Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled biotech-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |